Study guide
3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps
Key Takeaways Explain This Topic AI
Leiomyomas are benign monoclonal smooth-muscle tumors present in up to 70%–80% of women by age 50; Black women develop them earlier and with more symptoms.
FIGO types 0–2 (submucosal) cause heavy bleeding and infertility and are treated by hysteroscopic myomectomy; types 3–8 cause bulk and pressure symptoms.
Oral GnRH antagonist combinations (elagolix/estradiol/norethindrone acetate and relugolix/estradiol/norethindrone acetate) treat fibroid-related heavy bleeding for up to 24 months but are contraindicated with high thrombotic risk, including smokers over 35.
Adenomyosis causes heavy, painful menses with a diffusely enlarged, globular, tender uterus; MRI shows a junctional zone of 12 mm or more, and the LNG-IUS is first-line medical therapy.
Endometrial polyps cause intermenstrual bleeding and are removed hysteroscopically when symptomatic or postmenopausal; every removed cervical or endometrial polyp is sent for pathology.
Last updated: October 2026
Uterine Leiomyomas (Fibroids)
Leiomyomas are benign, monoclonal smooth-muscle tumors of the myometrium and the most common pelvic tumor in women. Up to 70%–80% of women have them by age 50. They are estrogen- and progesterone-responsive, so they grow during the reproductive years and usually shrink after menopause.
Risk Factors
Increased risk: Black race (earlier onset, larger and more numerous fibroids), increasing age until menopause, early menarche, nulliparity, obesity, family history, and vitamin D deficiency.
Decreased risk: Parity and use of combined hormonal contraception or DMPA.
FIGO Classification
- FIGO Type Location Typical Symptom
- 0 Pedunculated, entirely intracavitary Heavy bleeding, infertility
- 1 Submucosal, <50% intramural Heavy bleeding, infertility
- 2 Submucosal, ≥50% intramural Heavy bleeding, infertility
- 3–4 Intramural (3 touches the endometrium) Bleeding, bulk
- 5–7 Subserosal to pedunculated subserosal Pressure, urinary frequency, constipation
- 8 Other (cervical, parasitic) Varies
- Clinical Presentation
Most fibroids are asymptomatic. Symptoms include heavy menstrual bleeding with iron deficiency anemia, pelvic pressure, urinary frequency, constipation, and an enlarged, irregular, firm, mobile uterus on bimanual exam. In pregnancy, fibroids can undergo red (carneous) degeneration , causing acute localized pain in the second trimester that is managed with rest and short-term analgesia; they also raise risks of malpresentation and postpartum hemorrhage.
Diagnosis
Transvaginal ultrasound is first-line. Saline infusion sonohysterography or hysteroscopy maps submucosal fibroids, and MRI maps multiple fibroids before myomectomy or embolization.
Warning
Rapid growth of a presumed fibroid after menopause , or a mass with irregular vascularity and necrosis on imaging, raises concern for leiomyosarcoma . The FDA warns against power morcellation of presumed fibroids in peri- and postmenopausal women and allows only contained morcellation in carefully selected patients.
Medical Management
Option Notes
NSAIDs and tranexamic acid Reduce menstrual blood loss; tranexamic acid is avoided with active thromboembolic disease
- LNG-IUS (52 mg) Effective when the cavity is not distorted; higher expulsion with submucosal fibroids
- Combined hormonal contraceptives Reduce bleeding but do not shrink fibroids
Oral GnRH antagonist combinations Elagolix/estradiol/norethindrone acetate (Oriahnn) and relugolix/estradiol/norethindrone acetate (Myfembree) treat heavy bleeding for up to 24 months ; boxed warning for thromboembolic and vascular events; contraindicated with high VTE risk, smokers over 35, osteoporosis, and liver disease
GnRH agonist (leuprolide) Short preoperative course (3–6 months) shrinks fibroids by 30%–50% and lets iron restore hemoglobin; add-back therapy for longer use
- Iron Oral or IV iron corrects anemia before surgery
- Procedural Management by Goal
Desires future fertility: Hysteroscopic myomectomy for types 0–2; laparoscopic or abdominal myomectomy for intramural or subserosal fibroids.
Uterine preservation without pregnancy plans: Uterine artery embolization (UAE), radiofrequency ablation, or MR-guided focused ultrasound. UAE is generally not first choice for patients planning pregnancy.
Definitive: Hysterectomy, the only cure. ACOG recommends bilateral salpingectomy at the time of hysterectomy for ovarian cancer risk reduction.
Adenomyosis
Adenomyosis is the presence of endometrial glands and stroma within the myometrium , causing smooth-muscle hypertrophy.
Risk factors: Multiparity, age 40–50, and prior uterine surgery such as cesarean or curettage.
Presentation: Heavy menstrual bleeding, severe secondary dysmenorrhea, and dyspareunia, with a diffusely enlarged, globular, symmetric, boggy, tender uterus , typically no larger than a 12–14-week pregnancy.
Imaging: TVUS shows asymmetric myometrial thickening, myometrial cysts, and a "venetian blind" pattern of shadowing; MRI shows a junctional zone of 12 mm or more .
Treatment: The LNG-IUS is first-line medical therapy; NSAIDs, continuous hormonal contraceptives, progestins, and GnRH analogues also help. Hysterectomy is the definitive treatment, with histology confirming the diagnosis. Adenomyosis often coexists with endometriosis and fibroids.
Endometrial and Cervical Polyps
Feature Endometrial Polyp (AUB-P) Cervical (Endocervical) Polyp
Description Overgrowth of endometrial glands and stroma on a vascular stalk Smooth, red, fragile growth protruding from the os
Symptoms Intermenstrual or postmenopausal bleeding, heavy menses, infertility Postcoital spotting or discharge; often incidental
Risk factors Age, obesity, unopposed estrogen, tamoxifen Multiparity, ages 40–60
Diagnosis TVUS (best in the proliferative phase) or saline infusion sonohysterography; hysteroscopy Speculum exam
Malignancy risk Low, but higher in postmenopausal women with bleeding Very low
Treatment Hysteroscopic polypectomy if symptomatic, postmenopausal, or affecting fertility Office twisting removal with ring forceps; hemostasis with silver nitrate or Monsel's solution
Send every removed polyp for pathology. A small, asymptomatic endometrial polyp in a premenopausal woman may be observed, because some regress.
Clinical Pearls and Exam Traps
Fertility: Submucosal fibroids (types 0–2) lower implantation and raise miscarriage rates, so removing them improves fertility. Intramural fibroids that do not distort the cavity have uncertain effects, and subserosal fibroids do not affect fertility; removing them for fertility alone is not recommended.
Acute presentations: A prolapsing submucosal fibroid can appear at the cervical os with heavy bleeding and cramping; it is removed vaginally. A pedunculated subserosal fibroid can twist and cause acute pain like adnexal torsion.
Menopause: Fibroids usually shrink after menopause. Menopausal hormone therapy may cause slight growth, but a growing uterine mass in a postmenopausal woman who is not taking hormones needs evaluation for sarcoma.
Anemia: Check a CBC and ferritin in every patient with heavy bleeding, and correct iron deficiency before any procedure.
Tranexamic acid is taken only during menses (1.3 g three times daily for up to 5 days) and is avoided with active or prior thromboembolic disease; use extra caution when combined with estrogen-containing contraception.